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Summary
The rat ErbB2 (rErbB2) protein is a 185-kDa glycoprotein belonging to the epidermal growth
factor-related proteins (ErbB) of receptor tyrosine kinases. Overexpression and mutations of ErbB
proteins lead to several malignancies including breast, lung, pancreatic, bladder and ovary
carcinomas. ErbB2 is immunogenic and is an ideal candidate for cancer immunotherapy. We
investigated the possibility of expressing the extracellular (EC) domain of rErbB2 (653 amino
acids, aa) in Nicotiana benthamiana plants, testing the influence of the 23 aa transmembrane
(TM) sequence on protein accumulation. Synthetic variants of the rErbB2 gene portion encoding
the EC domain, optimized with a human codon usage and either linked to the full TM domain
(rErbB2_TM, 676 aa), to a portion of it (rErbB2-pTM, 662 aa), or deprived of it (rErbB2_noTM,
653 aa) were cloned in the pEAQ-HT expression vector as 6X His tag fusions. All rErbB2 variants
(72–74.5 kDa) were transiently expressed, but the TM was detrimental for rErbB2 EC
accumulation. rERbB2_noTM was the most expressed protein; it was solubilized and purified
with Nickel affinity resin. When crude soluble extracts expressing rErbB2_noTM were
administered to BALB/c mice, specific rErbB2 immune responses were triggered. A potent
antitumour activity was induced when vaccinated mice were challenged with syngeneic
transplantable ErbB2+ mammary carcinoma cells. To our knowledge, this is the first report of
expression of rErbB2 in plants and of its efficacy in inducing a protective antitumour immune
response, opening interesting perspectives for further immunological testing.
Introduction
Cancer is a leading cause of death worldwide, and a major
unmet need is to radically improve the survival of cancer
patients and find new therapies. Nowadays, surgery, radiation
and chemotherapy are the main anticancer weapons, often
causing adverse side effects. Cancer immunotherapy harnesses
the body’s immune system to fight against diverse tumours,
without developing resistance (Couzin-Frankel, 2013), but can
be successful only if it targets an oncoantigen, a tumour-
associated antigen with strong oncogenic properties and unlike
to escape immune recognition (Iezzi et al., 2012; Lollini et al.,
2006). ErbB2 is a 185-kDa transmembrane protein with tyrosine
kinase activity, that is expressed at low levels in normal tissue
but overexpressed in 25%–30% of breast cancers and in other
malignancies (Kern et al., 1990; Lei et al., 1995; Sato et al.,
1992; Slamon et al., 1989). ErbB2 is the main oncoantigen for
breast cancer (Lollini et al., 2006). Current treatment of ErbB2+
positive cancers includes passive administration of monoclonal
antibodies (Mab) against ErbB2, use of drugs that inhibit its
enzymatic activity (den Hollander et al., 2013), or the recently
approved antibody–drug conjugates (Peddi and Hurvitz, 2014).
ErbB2 is immunogenic (Napoletano et al., 2009; Quaglino et al.,
2004, 2011) and vaccines inducing antibodies against it are
under study (Baselga et al.,1998; Jacob et al., 2006; Li et al.,
2013; Quaglino et al., 2010).
Plants are regarded as biotechnological tools for producing
candidate vaccines against human or animal diseases (Chen,
2008; Rybicky, 2010); plant-made antigens have been already
tested in clinical trials and administered orally, with successful
outcomes (Kapusta et al., 1999; Pniewski et al., 2011; Tacket
et al., 1998). Plant cells can produce single or multiple proteins
that can assemble in high-order structures also serving as protein
expression platforms to present heterologous epitopes (Matic
et al., 2011; Thuenemann et al., 2013). In this work, we
investigated the expression in Nicotiana benthamiana plants of
the extracellular (EC) moiety of the rat ErbB2 (rErbB2) oncoan-
tigen and tested the immunogenicity and antitumour activity of
the plant-made protein.
Results
The EC domain of rErbB2 can be transiently expressed in
N. benthamiana
To express the rErbB2 gene in plants, we started with the
sequence encoding the EC domain to avoid the risks of
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manipulating the full protein and particularly the oncogenic
intracellular region. Moreover, considering the membrane
anchoring role of the transmembrane (TM) domain (23 aa) in
mammalian cells, three gene variants were tested for expression
in plants, that is rErbB2_TM (encoding the EC and TM domain, aa
1-676), rErbB2_pTM (encoding the EC and only 9 aa of the TM
domain, aa 1-662) and rErbB2_noTM (encoding only the EC
moiety, aa 1-653). All variants were synthetically produced in vitro
with optimized human codons. Synthetic genes were cloned in
the pEAQ-HT vector, downstream of a 6X His-tag coding
sequence (Figure 1). Following agro-infiltration, leaf extracts
were analysed in Western blot using Mabs specific for ErbB2
and the His tag. After direct extraction in Laemmli sample buffer,
polypeptides of about 72–73 kDa were detected only in tissue
infiltrated with the rErbB2_pTM and rErbB2_noTM constructs
(Figure 2a). To ascertain whether the lack of rErbB2_TM detec-
tion derived from lower expression or an intrinsic difficulty of
extraction, leaf tissue samples were treated by a trichloroacetic
acid (TCA)/acetone procedure. By this, the amount of extractable
rErbB2_pTM and rErbB2_noTM proteins increased, and traces of
rErbB2_TM became detectable (Figure 2a). Using known
amounts of a recombinant rErbB2 protein from E. coli as a
quantification standards, yields of 5, 60 and 280 lg per mg of
fresh leaf tissue were calculated for rErbB2_TM, rErbB2_pTM and
rErbB2_noTM, respectively.
The yield of rErbB2_noTM increased until approximately 6 days
post infiltration (dpi) (Figure 2b) and was maintained for about
10 days, with occasional yellowing and necrosis of the infiltrated
area (not shown).
The above results indicate that the EC moiety of rErbB2 can be
successfully expressed in plants, but the TM domain negatively
influences its accumulation. Based on yield, all further assays were
carried out with rErbB2_noTM.
rErbB2_noTM solubilization and purification
To prepare plant extracts containing rErbB2_noTM in a soluble
form suitable for mice immunizations, leaf tissue expressing the
recombinant protein was incubated with either phosphate or
Tris–HCl buffers at neutral pH, containing different combinations
of ionic or nonionic detergents (i.e. Tween-20, Triton X-100 or
SDS at 0.05%–0.5%). Many plant proteins were soluble in these
conditions, but rErbB2_noTM was never detected in soluble
fractions (not shown), unless 5 mM DTT and either 300 mM NaCl
or 8 M urea were added to the extraction mixtures (see
Experimental procedure, Buffers A and B and Figure 3a).
The His-tagged rErbB2_noTM (72.5 kDa) was purified from
crude soluble extracts made in a buffer containing 300 mM NaCl
using Nickel affinity resin (Figure 3b). The additional high
molecular weight molecules that eluted from the column and
reacted with the anti-ErbB2 Mab (Figure 3b) may be aggregates
rErbB2_noTM MELAAWCRWGFLLALLPPGIAGTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYVPANASLSFLQDIQEVQGYMLIAHNQVKRVPLQRLR
rErbB2_pTM  MELAAWCRWGFLLALLPPGIAGTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYVPANASLSFLQDIQEVQGYMLIAHNQVKRVPLQRLR
rErbB2_TM   MELAAWCRWGFLLALLPPGIAGTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYVPANASLSFLQDIQEVQGYMLIAHNQVKRVPLQRLR
101                                                                                              200
rErbB2_noTM IVRGTQLFEDKYALAVLDNRDPQDNVAASTPGRTPEGLRELQLRSLTEILKGGVLIRGNPQLCYQDMVLWKDVFRKNNQLAPVDIDTNRSRACPPCAPAC
rErbB2_pTM  IVRGTQLFEDKYALAVLDNRDPQDNVAASTPGRTPEGLRELQLRSLTEILKGGVLIRGNPQLCYQDMVLWKDVFRKNNQLAPVDIDTNRSRACPPCAPAC
rErbB2TM   IVRGT QLFEDKYALAVLDNRDPQDNVAASTPGRTPEGLRELQLRSLTEILKGGVLIRGNPQLCYQDMVLWKDVFRKNNQLAPVDIDTNRSRACPPCAPAC
(a)
_
201                                                                                              300
rErbB2_noTM KDNHCWGESPEDCQILTGTICTSGCARCKGRLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMHNPEGRYTFGASCVTTC
rErbB2_pTM  KDNHCWGESPEDCQILTGTICTSGCARCKGRLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMHNPEGRYTFGASCVTTC
rErbB2_TM   KDNHCWGESPEDCQILTGTICTSGCARCKGRLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMHNPEGRYTFGASCVTTC
301                                                                                              400
rErbB2_noTM PYNYLSTEVGSCTLVCPPNNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLRGARAITSDNVQEFDGCKKIFGSLAFLPESFDGDPSSGIAPLRPEQLQV
rErbB2_pTM  PYNYLSTEVGSCTLVCPPNNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLRGARAITSDNVQEFDGCKKIFGSLAFLPESFDGDPSSGIAPLRPEQLQV
rErbB2_TM   PYNYLSTEVGSCTLVCPPNNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLRGARAITSDNVQEFDGCKKIFGSLAFLPESFDGDPSSGIAPLRPEQLQV
401                                                                                              500
rErbB2_noTM FETLEEITGYLYISAWPDSLRDLSVFQNLRIIRGRILHDGAYSLTLQGLGIHSLGLRSLRELGSGLALIHRNAHLCFVHTVPWDQLFRNPHQALLHSGNR
rErbB2_pTM  FETLEEITGYLYISAWPDSLRDLSVFQNLRIIRGRILHDGAYSLTLQGLGIHSLGLRSLRELGSGLALIHRNAHLCFVHTVPWDQLFRNPHQALLHSGNR
rErbB2_TM   FETLEEITGYLYISAWPDSLRDLSVFQNLRIIRGRILHDGAYSLTLQGLGIHSLGLRSLRELGSGLALIHRNAHLCFVHTVPWDQLFRNPHQALLHSGNR
501 600
rErbB2_noTM PEEDCGLEGLVCNSLCAHGHCWGPGPTQCVNCSHFLRGQECVEECRVWKGLPREYVSDKRCLPCHPECQPQNSSETCFGSEADQCAACAHYKDSSSCVAR
rErbB2_pTM  PEEDCGLEGLVCNSLCAHGHCWGPGPTQCVNCSHFLRGQECVEECRVWKGLPREYVSDKRCLPCHPECQPQNSSETCFGSEADQCAACAHYKDSSSCVAR
rErbB2_TM   PEEDCGLEGLVCNSLCAHGHCWGPGPTQCVNCSHFLRGQECVEECRVWKGLPREYVSDKRCLPCHPECQPQNSSETCFGSEADQCAACAHYKDSSSCVAR
601                                                653      662           676
rErbB2_noTM CPSGVKPDLSYMPIWKYPDEEGICQPCPINCTHSCVDLDERGCPAEQRASPVT-----------------------
rErbB2_pTM  CPSGVKPDLSYMPIWKYPDEEGICQPCPINCTHSCVDLDERGCPAEQRASPVTFIIATVVGV--------------
rErbB2_TM   CPSGVKPDLSYMPIWKYPDEEGICQPCPINCTHSCVDLDERGCPAEQRASPVTFIIATVVGVLLFLILVVVVGILI
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Figure 1 rErbB2 variants and constructs description. (a) ClustalW alignment of the EC domains of the rErbB2 proteins, with the TM domain indicated in
green. (b) Scheme of the T-DNA regions within the right and left borders (RB and LB). The rErbB2 synthetic genes fused to the 6X His tag (His) of pEAQ-HT
are under the control of the CaMV promoter (CaMV-P), between the 50 and 30 untranslated regions (NTR) of the RNA-2 of Cowpea mosaic virus and the
nopaline synthase terminator (Nos-T). pEAQ-HT also includes the silencing suppressor p19, under CaMV promoter and terminator (CamMV-P and -T).
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derived from misfolded ErbB2 polypeptides or, alternatively,
ErbB2 oligomers; it is known that ErbB2 forms biologically active
dimers/oligomers when overexpressed in mammalian cells and
the EC domain alone is sufficient for such multimerization
(Brennan et al., 2000). For the low yield of purified protein
obtained (about 2 lg/g fresh leaf tissue), crude soluble extracts
prepared in buffer A were used for mice immunizations; buffer A
was preferred for the absence of chaotropic agents.
Soluble plant-derived rErbB2_no TM elicits specific anti-
rErbB2 antibodies
To determine the immunogenicity of the plant-made
rErbB2_noTM, soluble extracts containing the recombinant pro-
tein were administered to BALB/c mice by subcutaneous injection
(12 lg of plant-derived rErbB2 per dose). Animals vaccinated
with control extracts infiltrated with the empty pEAQ-HT plasmid
did not develop any specific response; instead, a significant
amount of anti-rErbB2 antibodies was detected in sera of mice
vaccinated with rErbB2_noTM (Figure 4a and b). In spite of the
evident and measurable humoral immune response elicited in
mice by the plant rErbB2 protein, only a negligible cytotoxic-
specific response against cells pulsed with the immune-dominant
rErbB2 peptide (TYVPANASL) was determined in all mice
(Figure S1) by an in vivo cytotoxicity assay (Quaglino et al., 2010).
Mice immunized with plant-derived rErbB2_noTM
exhibit antitumour activity
The antitumour activity of the plant-made rErbB2_noTM protein
was evaluated by in vivo tumour rejection experiments, challeng-
ing vaccinated mice with a lethal dose of TUBO cells. A growing
tumour occurred in all mice vaccinated with control extracts
(empty pEAQ-HT plasmid; n = 9), whereas a tumour developed
only in one of eight mice vaccinated with extracts expressing
rErbB2_noTM (Figure 4c). Moreover, the time required by this
single tumour to exceed a 10-mm threshold was 55 days, while
the same tumour size was reached after about 33  2 days in
mice treated with the empty pEAQ-HT vector (Figure 4d).
Importantly, mice vaccinated with extracts expressing the
rErbB2_noTM protein necroscopied at the end of the experiment
were free from overt signs of autoimmune lesions in the heart,
kidney and liver (data not shown).
Discussion
The potential low production costs, combined to minor biological
risks, ease of scaling up and the ability of plants to provide an
endomembranous system suitable for protein folding, assembly
and post-translational modifications similar to mammalian sys-
tems are interesting advantages of plant expression platforms
(Ma et al., 2005; Thuenemann et al., 2013). No current
recombinant expression strategies offer the cheapness and speed
of protein production, such as transient expression in plants.
Transient expression is based on the delivery of the T-DNA region
carrying the gene(s) of interest from Agrobacterium tumefaciens
to the plant nucleus, followed by transcriptional and translational
activation without T-DNA integration into the plant nuclear
genome. Agrobacteria carrying the gene(s) of interest can be
delivered into the intercellular spaces of parenchyma through
agroinfiltration (Gelvin, 2003; Kapila et al., 1997), leading in few
days or weeks to the accumulation of proteins in planta at yields
suitable for industrial-scale production (Marillonnet et al., 2005;
Sainsbury and Lomonossoff, 2008). Here, we investigated how to
properly express an active portion of the rErbB2 receptor in
plants, using a transient expression system based on a simple and
efficient vector (Sainsbury et al., 2009). We clearly demonstrated
that following agroinfiltration of N. benthamiana with vectors
carrying synthetic sequences encoding the EC domain of a
humanized rErbB2 gene, significant yields of rErbB2 protein are
achieved.
Many factors contribute to the accumulation of a recombinant
protein in plants, among which its structure, stability and
solubility that ultimately depend also on its route of destination
into the cell and interference with host cell components (Barbante
et al., 2008; Streatfield, 2007).
The TM sequence that in our constructs was present at the
C-terminus of the EC domain of rErbB2 was expected to provide
membrane anchorage of the protein and possibly have a
stabilizing effect. However, such TM domain was detrimental
for rErbB2 accumulation. The structure of the three variants
predicted using the RaptorX server (http://raptorx.uchicago.edu/)
was not significantly altered when the TM was partially or totally
deleted (not shown). An extraction procedure more suitable for
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Figure 2 Transient expression in N. benthamiana of the synthetic rErbB2
genes fused to 6X His tag. (a) Comparative Western blot of total proteins
extracted from leaf samples (0.5 mg fresh tissue/lane) infiltrated with the
three rErbB2 variants or with the empty pEAQ-HT (control) at 5 dpi,
probed with the anti-ErbB2 or the anti 6X His Mabs (upper and middle
panel, respectively). The large subunit of Rubisco is shown as loading
control (lower panel). rErbB2 is indicated with an arrowhead. An aliquot of
330 ng of rErbB2 protein produced in E. coli (Cat. No# 028823286;
Genway) was loaded as quantification standard. (b) Time course of
rErbB2_noTM accumulation (4–6 dpi). In both panels, protein molecular
weight standards are indicated on the right (in kDa).
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membrane-bound proteins (Wu and Wang, 1984) improved the
pulling out of rErbB2 polypeptides from the plant tissue, allowing
rErbB2_TM detection, though only in traces. This was suggestive
of a different localization of rErbB2_noTM and rErbB2_TM within
the plant cell. In silico subcellular targeting analyses of the
EC rErbB2 sequences with or without the TM domain pre-
dicted similar destinations for the two proteins, that is mitochon-
drion or secretory pathways using the TargetP 1.1 server
(www.cbs.dtu.dk/services/TargetP) or plasma membrane with
the LocTree server (https://rostlab.org/services/loctree2). Con-
versely, the PSort tool (http://psort.hgc.jp/) was discriminatory,
predicting the mitochondrial inner membrane, chloroplast thyla-
koid, or plasma membrane for rErbB2_TM (scores 0.9, 0.7 and
0.7, respectively) and the mitochondrial matrix space for
rErbB2_noTM (score 0.7). Our attempts to localize and discrim-
inate the rErbB2 variants in plant cells suffered from a poor level
of expression of the green fluorescent protein (GFP)-rErbB2
fusions compared to GFP alone (Supplementary Materials in
Appendix S1 and Figure S2a) that justified the addition of a
silencing suppressor protein during agroinfiltration. Laser scan-
ning confocal fluorescence analysis of tissue expressing GFP alone
or the GFP-rErbB2_noTM and GFP-rErbB2_TM fusion proteins did
not reveal clear differences between the two recombinant
proteins that could prove a differential cellular targeting
(Figure S2b), leaving still open the discussion on the negative
effect of the TM sequence on rErbB2 yield.
The efficient expression system employed, coupled to a simple
solubilization procedure, allowed us to obtain appropriate
amounts of rErbB2_noTM in <2 weeks. Recently, the expression
of the EC domain of human ErbB2 in Pichia pastoris and its
biological activity were reported (Dimitriadis et al., 2009). Nota-
bly, the yeast-made protein migrated as a 120- to 210-kDa
polypeptide, interpreted as indicative of heavy mannosylation. As
the EC domain of ErbB2 expressed by transduced human cells
(that cannot perform mannosylation) has no antineoplastic role,
while the yeast-derived protein had significant antitumour effect
in mice, the authors concluded that mannosylation was an
essential trait (Dimitriadis et al., 2009). An in silico analysis of
glycosylation in eukaryotes with the GlycoEP server (Cauhan
et al., 2013) predicted six potentially N-glycosylated residues for
the rErbB2 EC domain (i.e. N68, N188, N260, N531, N572 and
N630), the first five of which were also predicted by the NetNGlyc
server (http://www.cbs.dtu.dk/services/NetNGlyc). Although the
plant-made rErbB2_noTM still awaits a biochemical characteriza-
tion, its migration as a 72-kDa polypeptide let us to speculate that
no heavy glycosylation had occurred. The potent protecting effect
of such protein in mice following challenge albeit with rErbB2+
tumour cells allows to reasonably conclude that its strong
immunogenicity and protecting activity occur irrespective of its
glycosylation pattern.
As anti-rErbB2 antibody production was the prominent
immune response induced by vaccination, we speculate that
the plant-made rErbB2 EC moiety exposes native conformational
epitopes in a correct configuration. The vaccine formulation used
in this study elicited a significant and effective humoral antitu-
mour immune response, albeit with negligible cellular cytotoxicity
(Figure S1A). This failure could be explained considering the
nature of the vaccine; as a soluble protein, peptides derived from
it are presented to T cells mainly through MHC class II antigen,
thus triggering CD4+, but not CD8+ T cells. Of course, cross-
presentation can occur, but probably in a way insufficient to
induce a measurable cytotoxic T-cell response. Constructs encod-
ing fusion proteins consisting of the ErbB2-EC domain linked to a
molecular moiety that facilitates antigen uptake and presentation
by dendritic cells could be designed to elicit significant T-cell
response (Sloots et al., 2008; Zizzari et al., 2011).
This work represents one of the first successful assays to use
plant-expressed vaccines against cancer, providing a reagent
suitable to design further immunotherapeutic strategies for anti
tumour vaccination purposes. Conclusively, our data could be of
impact for the scientific community, speeding up the translation
of a new, nontoxic management modality to treat human cancer
patients, hopefully contributing to improve their survival.
Experimental procedures
Gene synthesis and cloning of rErbB2
Three genes encoding the EC domain of the rErbB2 protein linked
to a full (TM) domain (1965 nt) (rErbB2_TM), a partial TM (1923
nt) (rErbB2_pTM) or without TM (1896 nt) (rErbB2_noTM)
(Figure 1a) were synthesized with an optimized human codon
usage by GeneArt (Thermo Fisher Scientific, Waltham, MA)
(rErbB2_TM) or GenScript (Piscataway, NJ) (rErbB2_pTM and
rErbB2_noTM). Genes were subcloned into the plant expression
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Figure 3 Preparation of soluble extracts for mice
immunization and protein purification. (a) Protein
solubilization. Leaf tissue agroinfiltrated with
pEAQ-HT or rErbB2_noTM was extracted in
buffers A and B (see Experimental procedure);
soluble fractions were denatured in Laemmli
sample buffer and tested in Western blot using
the anti-ErbB2 antibody; a Coomassie stained gel
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(b) Purification of rErbB2_noTM by Nickel affinity
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steps were denatured and tested in Western blot;
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panels, protein molecular weight standards are
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vector pEAQ-HT (Sainsbury et al., 2009) (Figure 1b) fused to the
sequence encoding the 6XHis tag.
Transient expression in plants
Constructs made in pEAQ-HT were transformed into A. tumefac-
iens LBA4404 and delivered to N. benthamiana plants by
agroinfiltration (Noris et al., 2011), using the empty pEAQ-HT
vector as control. Plants were grown at 23 °C (16/8 h light/dark).
At the appropriate times, agroinfiltrated tissue was homogenized
in Laemmli sample buffer (9 lL/mg fresh leaf) and boiled for
2 min. Alternatively, total proteins were extracted from infiltrated
tissue using trichloroacetic acid (TCA, extensively washed with
acetone (Wu and Wang, 1984) and denatured in Laemmli sample
buffer. Protein electrophoresis and Western blot were performed
as described (Matic et al., 2011), using anti-ErbB2 Mab
(WH0002064M6; Sigma, St. Louis, MO, 1 : 1000 dilution) or
anti-6XHis Mab (Thermo Fisher Scientific, Rockford, IL, 1 : 2000
dilution), in parallel experiments. The plant-derived rErbB2 anti-
gen was quantified by comparing the intensity of the signal
detected in Western blot with that of a series of dilutions of a
recombinant rErbB2 protein produced in E. coli (cat#1028823286;
Genway, San Diego, CA), ranging from 33 to 660 ng/lane, used as
standard. Quantification of signal intensities was performed with the
ImageJ software (http://imagej.nih.gov/ij/).
Preparation of soluble protein extracts and
rErbB2_noTM purification
Leaves expressing rErbB2_noTM were collected 5 dpi, lyophilized,
homogenized with liquid N2 and extracted (33 lL/mg dry tissue)
with Buffer A (50 mM Na-phosphate buffer, pH 8.0, 300 mM
NaCl, 10 mM EDTA, 2.5 mM DTT, 0.5 mM PMSF, 0.2% Tween-20) or
Buffer B (8 M urea, 10 mM EDTA, 2.5 mM DTT, 0.5 mM PMSF in PBS).
After a brief incubation, homogenates were centrifuged (15300 g,
15 min, 4 °C) and supernatants stored at 20 °C. For protein
purification, leaf tissue was extracted in a modified Buffer A including
10 mM imidazole, but lacking DTT and EDTA, loaded in batch onto Ni-
NTA Agarose beads (Qiagen Inc., Valencia, CA). Proteins were eluted
with 100 mM imidazole, following manufacturer instructions.
Mice immunizations
BALB/c female mice (Charles River, Calco, Italy) were bred at the
Molecular Biotechnology Center (Torino, Italy) and treated
according to the European Guidelines and policies, as approved
by the University of Torino Ethical Committee. Two groups of
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Figure 4 Antibody and antitumour response against rErbB2 induced by plant-derived rErbB2_noTM immunization. (a, b) Induction of specific anti-rErbB2
antibodies in sera of BALB/c mice immunized with extracts from leaves infiltrated with pEAQ-HT (n = 9) or the rErbB2_noTM (n = 8) plasmid measured by
flow cytometry (a) and ELISA (b). Anti-rErbB2 antibody titres are expressed as mean fluorescence intensity (MFI) or optical density (OD) values for each
vaccinated mice. Horizontal lines represent the geometric mean of each experimental group. ***P < 0.0001 (Student’s t-test). (c) Antitumour protection
against TUBO cells. Tumour incidence of BALB/c mice vaccinated with extracts from leaves infiltrated with the recombinant pEAQ-HT (n = 9; dotted lines)
or rErbB2_noTM (n = 8; continuous lines) plasmid. ***P = 0.0001 (log-rank Mantel–Cox test). (d) Tumour speed of growth. Each line refers to an
individual tumour; the number of mice that rejected the tumour/total mice in the group of rErbB2_noTM vaccinated mice is in brackets.
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10-week-old mice received three subcutaneous injections at
biweekly intervals with 150 lL leaf extracts expressing
rErbB2_noTM or infiltrated with pEAQ-HT (control). Extracts were
emulsified with equal volumes of complete or incomplete
Freund’s adjuvant (Sigma), immediately before injection. Mice
were bled 2 weeks after the third vaccination, and sera were
stored at 20 °C.
Anti-rErbB2 antibody immune response
Sera from immunized mice were tested by flow cytometry for
their ability to bind NIH3T3 murine fibroblasts expressing rErbB2
(3T3/NKB cells; 25) and by ELISA. For flow cytometry, 3T3/NKB
cells were cultured in DMEM with Glutamax 1 (Life Technologies,
Monza, Italy) supplemented with 20% heat-inactivated fetal
bovine serum (FBS), G418 and zeocin (all Invitrogen, Monza, Italy;
the last two 0.6 mg/mL). 3T3/NKB cells were pretreated with Fc
receptor blocker (CD16/CD32; BD Biosciences, Milano, Italy)
(15 min, 4 °C) and incubated (30 min, 4 °C) with 20-fold diluted
mice sera. Total IgG binding was evaluated using a FITC-
conjugated goat anti-mouse IgG Fc antibody (DakoCytomation,
Glostrup, Denmark). The Ab4 Mab (Oncogene Research Products,
La Jolla, CA) was used as positive control. Flow cytometry was
performed with a CyAn ADP (DakoCytomation, Beckman Coul-
ter, Milano, Italy). Results are expressed as mean fluorescence
intensity (MFI) and analysed with Summit 4.2 (DakoCytomation)
software.
For ELISA, 96-well plates (Costar; Sigma-Aldrich) were coated
with 100 ng per well of recombinant rErbB2 protein from E. coli
(Genway) overnight at 4 °C. Coated plates were then blockedwith
10% Newborn Calf Serum (NCBS; Sigma-Aldrich) in PBS (Invitro-
gen)-0.05% Tween (Sigma-Aldrich) buffer for 2 h at 37 °C. Plates
were incubated with mice sera diluted 20-fold in 1% blocking
buffer for 1 h at 37 °C. Plates werewashed three times with a PBS-
Tween buffer. The HRP-conjugated anti-mouse IgG antibody
(Sigma-Aldrich) (1 : 2000 dilution in blocking buffer) was incu-
bated for 1 h at 37 °C. Plates were washed six times, and
chromogenic 3,30,5,50-tetramethylbenzidine substrate was added
(TMB; Sigma-Aldrich). The reaction was stopped by the addition of
2N HCl; optical density (OD) was measured at 450 nm using a
microplate reader (680XR; Bio-Rad, Richmond, California, USA).
Differences in MFI and OD were analysed by Student’s t-test.
Anti tumour protection against rErbB2+ mammary TUBO
cells
Two weeks after the third immunization, mice were challenged
subcutaneously (s.c.) with a lethal dose (1 9 105) of rErbB2+
mammary carcinoma cells derived from a mammary carcinoma
arisen in a BALB/c female mouse transgenic for the activated
rErbB2 gene (BALB-neuT mice; Quaglino et al., 2008). TUBO cells
were cultured in DMEM with Glutamax 1 (Life Technologies) plus
20% heat-inactivated FBS (Invitrogen). Mice were weekly
inspected by palpation for tumour growth, regarding progres-
sively growing masses >1 mm in diameter as tumours. Mice were
sacrificed when one of the tumours exceeded 10 mm diameter.
Differences in tumour incidence were analysed by the log-rank
(Mantel–Cox) test.
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